Uzbekistan Medical Device Registration: Statutory Review Timelines Under Resolution No. 738
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The statutory review periods under Resolution No. 738 follow a six-tier structure: 15 working days for the recognition pathway; 30 working days for IVDs intended for epidemic or pandemic use; 60 working days for Class I; 60 working days for the WHO prequalification pathway; 90 working days for Class IIa; and 120 working days for Class IIb and Class III. The gap between the shortest and the longest tier is a factor of 8. These figures form the baseline of any project schedule, but they must be used together with the time that falls outside the review clock, described in article 15 of this series; used alone, they lead to a systematic underestimation of the project timeline and to launch commitments that the process cannot support.
When presenting the timeline to management or customers, quote the statutory tier and the correction reserve side by side, so that the gap between the nominal clock and the realistic duration is visible from the start rather than explained after a delay.
2. Legal basis
| Regulation | Reference number | Date | Provisions |
|---|---|---|---|
| Cabinet of Ministers Resolution approving the Regulation on State Registration of Medicinal Products and Medical Devices and the Issuance of Registration Certificates | No. 738 | Adopted November 24, 2025; effective February 26, 2026 | Statutory review periods: recognition 15 working days; epidemic-use IVDs 30 working days; Class I 60 working days; WHO prequalification 60 working days; Class IIa 90 working days; Class IIb and III 120 working days |
| Cabinet of Ministers Resolution approving the Regulation on State Registration of Medicinal Products and Medical Devices and the Issuance of Registration Certificates | No. 738 | Adopted November 24, 2025; effective February 26, 2026 | Time consumed by deficiency responses, document verification, clinical studies, and manufacturing inspections is not counted within the statutory review period |
| Cabinet of Ministers Resolution approving the Regulation on State Registration of Medicinal Products and Medical Devices and the Issuance of Registration Certificates | No. 738 | Adopted November 24, 2025 | In the specialized expert evaluation stage the deficiency correction period is 60 working days, and the clock is suspended while the applicant prepares its response |
| Cabinet of Ministers Resolution approving the Regulation on State Registration of Medicinal Products, Medical Products for Medical Use and Medical Equipment (superseded by Resolution No. 738) | No. 213 | March 23, 2018 (amended December 7, 2023) | Legacy reference: deficiency response 45 working days, full process 155 working days |
3. Expert insights
Insight one: the six-tier structure shows that the drafters placed both risk and evidence maturity inside the clock. The first two tiers, 15 and 30 working days, correspond to situations in which the evidence is already mature, either a foreign approval or an emergency use; the last four tiers, 60, 60, 90, and 120 working days, correspond to situations in which evidence must be generated locally. When a manufacturer seeks a shorter period, only two levers actually exist: raising evidence maturity by using the recognition pathway, or lowering the risk class through design changes or a narrowing of the intended purpose.
Insight two: Class I and WHO prequalification share the same 60 working days but carry different evidence burdens. Both run on 60 working days, yet the burden for Class I devices is that clinical effectiveness reports are generally not required, except for sterile, measuring, and invasive devices, while the burden for the WHO prequalification pathway is the verification of the prequalification documents themselves. The risk in the first case is a reclassification to a higher class; the risk in the second is the currency and coverage of the prequalification file.
Insight three: the 60 working day deficiency correction period is a double-edged sword. The correction period gives the applicant ample time, but the review clock is suspended during it. A Class I case nominally set at 60 working days that goes through two correction rounds can end up taking longer in real time than a well-prepared 90 working day case. Getting the dossier right the first time is therefore worth more than fighting for a lower tier.
Insight four: the legacy figure of 155 working days must not be used for new-case scheduling. Under Resolution No. 213 the full-process figure was 155 working days with a 45 working day deficiency response period. After Resolution No. 738 entered into force, the structure of the periods was rearranged, and the old values serve only as historical reference; they must not be used in schedule calculations for cases filed after February 26, 2026.
4. Practical recommendations
- Use the six-tier table to fix the baseline segment of the project, and record the applicable tier together with the basis for the classification in the schedule document.
- Build the schedule in two lines: the statutory review period in working days, and the time outside the clock in calendar days, each totaled separately.
- Adopt right-first-time as the quality objective: complete cross-document consistency checks before submission to reduce correction rounds.
- Pursue the two routes to a shorter period: raising evidence maturity through the recognition pathway, or lowering the risk class.
- Remove the legacy values of 45 and 155 working days from schedule templates to prevent accidental reuse.
5. Verification checklist
- □ The applicable statutory tier of the project is confirmed (15, 30, 60, 90, or 120 working days)
- □ The basis for the tier determination (pathway type, safety class) is recorded in the schedule document
- □ The schedule separates the statutory period and the time outside the clock into two lines
- □ Cross-document consistency checks are complete before submission, to reduce correction rounds
- □ The deficiency correction period (60 working days) is reserved in the schedule and marked with a clock suspension
- □ The legacy values (45 and 155 working days) are not used in the schedule for the new case
GRZAN provides registration support in Uzbekistan for manufacturers, importers, and authorized representatives, including statutory timeline analysis and project scheduling. For assistance, contact info@grzanglobal.com.
Regulatory information verified as of October 29, 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us